IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Aisling Capital Management LP

Q3 2019 Holdings

Filed 2019-11-13 | 13 holdings | $86.2M | 13F-HR | View on SEC ↗ · Holdings Table ↗

Sign in to see sub-manager breakdown

IssuerClassCUSIPValue ↓Shares% Portfolio
BridgeBio (Bbio)(BBIO)COM10806X102$82.4M3,835,72295.6%
Arcus Biosciences, Inc. (Rcus)(RCUS)COM03969F109$3.0M333,3333.5%
Aclaris Theraputics Inc (Acrs)(ACRS)COM00461U105$685.0K634,4550.8%
Eidos Therapeutics, Inc. (Eidix)(EIDXGBP)COM28249H104$40.4K1,123,6300.0%
Avrobio, Inc. (Avro)COM05455M100$12.6K893,0790.0%
ObsEva SA (Obsv)COMH5861P103$11.5K1,386,3380.0%
Marker Therapeutics, Inc. (Mrkr)COM57055L107$10.2K2,000,0000.0%
Aeglea Biotherapeutics Inc (Agle)(AGLEUSD)COM00773J103$9.9K1,291,1510.0%
Sunesis Pharmaceuticals, Inc. (Snss)COM867328700$7.3K10,100,0000.0%
Atreca (Bcel)(BCELUSD)CL A COM04965G109$4.7K387,6530.0%
Nabriva Therapeutics plc (Nbrv)SHSG63637105$3.8K1,910,2870.0%
Zosano Pharma Corporation (Zsan)COM98979H202$3.2K2,028,5710.0%
Verona Pharma plc (Vrna)(VRNA)COM925050106$2.0K443,5960.0%